NASDAQ:ANCN - ANCHIANO THERAP/S Stock Price, Forecast & News

ANCHIANO THERAP/S trades on the NASDAQ under the ticker symbol "ANCN."

ANCHIANO THERAP/S (NASDAQ:ANCN) posted its quarterly earnings results on Friday, November, 15th. The company reported ($2.26) EPS for the quarter, missing the consensus estimate of ($0.15) by $2.11. View ANCHIANO THERAP/S's Earnings History.

ANCHIANO THERAP/S is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for ANCHIANO THERAP/S.

3 brokerages have issued 12-month price objectives for ANCHIANO THERAP/S's stock. Their forecasts range from $12.00 to $16.00. On average, they expect ANCHIANO THERAP/S's stock price to reach $14.00 in the next year. This suggests a possible upside of 786.1% from the stock's current price. View Analyst Price Targets for ANCHIANO THERAP/S.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANCHIANO THERAP/S in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ANCHIANO THERAP/S.

News stories about ANCN stock have trended negative on Sunday, InfoTrie reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. ANCHIANO THERAP/S earned a media sentiment score of -2.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for ANCHIANO THERAP/S.

Some companies that are related to ANCHIANO THERAP/S include Forward Pharma A/S (FWP), IntelGenx Technologies (IGXT), PLx Pharma (PLXP), Acer Therapeutics (ACER), Moleculin Biotech (MBRX), Humanigen (HGEN), Soligenix (SNGX), Merrimack Pharmaceuticals (MACK), Jaguar Health (JAGX), Pharmaxis (PXSLY), Medicure (MCUJF), Seelos Therapeutics (SEEL), Evoke Pharma (EVOK), Leap Therapeutics (LPTX) and Celsion (CLSN).

Based on aggregate information from My MarketBeat watchlists, some companies that other ANCHIANO THERAP/S investors own include Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA), Artelo Biosciences (ARTL), BioNano Genomics (BNGO), Cronos Group (CRON), CytomX Therapeutics (CTMX), Kiniksa Pharmaceuticals (KNSA), Proteostasis Therapeutics (PTI), Spectrum Pharmaceuticals (SPPI) and Achieve Life Sciences (ACHV).

(ANCN) raised $35 million in an IPO on Tuesday, February 12th 2019. The company issued 2,400,000 shares at $14.55 per share. Oppenheimer served as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

Shares of ANCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANCN stock can currently be purchased for approximately $1.58.

ANCHIANO THERAP/S has a market capitalization of $11.72 million. The company earns $-13,280,000.00 in net income (profit) each year or ($5.25) on an earnings per share basis. ANCHIANO THERAP/S employs 19 workers across the globe.View Additional Information About ANCHIANO THERAP/S.

The official website for ANCHIANO THERAP/S is http://www.anchiano.com/.

ANCHIANO THERAP/S's mailing address is 1/3 HIGH-TECH VILLAGE GIVAT RAM P.0. BOX 39264, JERUSALEM L3, 9139102. The company can be reached via phone at 972-2548-6555 or via email at [email protected]